Novartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, ...

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech ...

Novartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen's technology for turning intravenous biologics ...

A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to ...

Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a ...

Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 ...

Novartis has paused eight clinical trials of its CD19 CAR-T therapy rap-cel after three patients died from a severe immune reaction. The studies are evaluating the therapy in autoimmune and ...

French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a ...

Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another ...

Swiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models ...

California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic ...

Swiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its ...